The pharmaceutical company behind a drug for amyotrophic lateral sclerosis (ALS) said it would start a process to remove it from the US and Canadian markets. Amylyx Pharmaceuticals said the drug for ALS also known as motor neurone disease (MND) or Lou Gehrig’s disease would no longer be available for new patients after a trial showed it did not work. “Patients currently on therapy in the US and Canada who, in consultation with their physician, wish to stay on treatment can be transitioned to a free drug [programme],” the company said. Trials showed no difference to placeboEarlier this month, A…